Replies to post #46566 on Biotech Values

[aslan2772]

"Some CoStar studies showed high or variable rates of "late-loss,""

Sounds a little like MDT's Endeavor.

Corio and Symbio are versions of Costar's platform with Pimecrolimus and dual Pemecrolimus/Paclitaxil, respectively, in a bioerodible polymer(s).

http://www.conormed.com/comp/news_49_051806.html

The cancellation of these programs in addition Costar is a bit of a shocker. Given the typically shrewd behavior of JNJ management, you have to wonder what is going on. Assuming that the failure of Costar was not a total surprise to JNJ, perhaps there is something else in the CONR pipe that JNJ values at 1.4B dollars. Even more puzzling is that JNJ recently canceled some of its future Cypher pipeline for the US. This is all very interesting indeed.